EW
ALNY icon

Evoke Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Evoke Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Buy
693
+72
+12% +$24.5K ﹤0.01% 618
2025
Q4 		$247K Sell
621
-275
-31% -$122K ﹤0.01% 575
2025
Q3 		$409K Buy
+896
New +$365K 0.01% 415
2021
Q2 		– Sell
-18
Closed -$3K – 1162
2021
Q1 		$3K Buy
+18
New +$2.71K ﹤0.01% 926

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Evoke Wealth's ALNY Position: Q1 2026 in Review

Evoke Wealth increased its Alnylam Pharmaceuticals (ALNY) stake by 12% in Q1 2026, buying an estimated $24.5K and bringing the position to 693 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #618.

Evoke Wealth first reported a position in ALNY in Q1 2021 and has held it in 4 quarters since. The position peaked at $409K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Evoke Wealth held 693 shares of Alnylam Pharmaceuticals worth $229K as of Q1 2026.
  • Evoke Wealth bought 72 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $24.5K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Evoke Wealth's portfolio in Q1 2026, its #618 holding.
  • Evoke Wealth first reported a position in Alnylam Pharmaceuticals in Q1 2021 and has held it in 4 quarters since.
  • Evoke Wealth's Alnylam Pharmaceuticals position peaked at $409K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Evoke Wealth's 13F filing for Q1 2026, filed 15 May 2026.